16.00 USD
▼-0.41-2.50%
盘后 15.88 -0.78%
2026-09-15
市值
$1.41B
市盈率
—
EPS
-0.58
股息率
—
52 周区间
16.00 – 40.48
成交量
4.29K
Beta
0.67
目标价
47.13
52W 低 16.0052W 高 40.48
价格走势
公司简介
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid...